Guinea-BissauTuberculosis profile
Population  2014 1.8 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.7–1.7) 63 (39–93)
Mortality (HIV+TB only) 1.5 (1.1–1.9) 81 (60–104)
Prevalence  (includes HIV+TB) 8.3 (4–14) 463 (224–787)
Incidence  (includes HIV+TB) 6.6 (4.7–8.9) 369 (261–495)
Incidence (HIV+TB only) 2.9 (2–4) 162 (110–224)
         
Case detection, all forms (%) 34 (26–49)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
36 (6–67) 8 (2–15)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 544   43
Pulmonary, clinically diagnosed 602   0
Extrapulmonary 93   0
       
Total new and relapse 2 282    
Previously treated, excluding relapses 6    
Total cases notified 2 288    
Among 2 282 new and relapse cases:
108 (5%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 83 (5%) 58 (118%) 583
Laboratory-confirmed RR-/MDR-TB cases     25
Patients started on MDR-TB treatment ***     17
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 510 (66)
HIV-positive TB patients 561 (37)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 282 (50)
HIV-positive TB patients on antiretroviral therapy (ART) 149 (27)
HIV-positive people screened for TB 11 420  
HIV-positive people provided with IPT 448  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (77) 2 236
Previously treated cases, excluding relapse, registered in 2013 (22) 9
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (40) 5
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 2.8
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 2.9
% Funded domestically 4%
% Funded internationally 94%
% Unfunded 3%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-10 Data: www.who.int/tb/data